FDA withdraws 11,000 vials of chlorthalidone from the market due to potential ineffectiveness in controlling blood pressure

The United States health regulatory agency, FDA, announced the recall of thousands of vials of a blood pressure medication. The measure affects more than 11,000 units of the product that may be ineffective in their use.
The official statement explains that the drug does not meet the required dissolution standards, compromising the way in which the active ingredient is released into the body. This failure can significantly reduce its therapeutic effectiveness for patients.
In an action released directly from Washington, the Food and Drug Administration (FDA) confirmed the recall of a considerable volume of medicines. More than 11 thousand units intended for the treatment of high blood pressure are being withdrawn from the market due to suspected lack of effect.
The collection action extends across the entire North American territory, involving exactly 11,460 bottles. The products in question are chlorthalidone tablets, USP, in a strength of 25 milligrams. The flaw identified, according to the official note, was again in the requirement to dissolve the medicine.
Understand the importance of dissolution tests for the effectiveness of medicines
FDA regulations establish that the dissolution test is crucial to verify how a drug disintegrates and releases its active components into body fluids. Failure to comply with these standards can lead to medication with less therapeutic effect or, in more serious cases, even to an inappropriately administered dose.
According to information from the Mayo Clinic, the compound chlorthalidone is a diuretic frequently prescribed to control high blood pressure. This is a very prevalent cardiovascular disease, which directly impacts the arteries and blood circulation in the body.

Therefore, failure to comply with strict dissolution criteria has the potential to seriously compromise the medicine’s ability to fulfill its function. Without adequate release of the active ingredient, the treatment may not achieve the expected results.
The bottles impacted by the recall contain either 100 or 1,000 tablets of the drug. The specific batches involved are RISA24001 and RISB24002, with the expiration date for all affected products set for April 2027.
The production of the tablets was carried out by Inventia Healthcare Limited, a company located in India. Distribution in the United States was handled by Rising Pharma Holdings, Inc., headquartered in East Brunswick, New Jersey.
Recent history of recalls due to dissolution failures
This recall episode is part of a context of ongoing concerns in the pharmaceutical sector. It comes about a month after a similar case, involving another hypertension medication, which was also withdrawn from the market for the same reason: flaws in dissolution specifications.
In May, tablets that combined amlodipine and olmesartan medoxomil had already been subject to a similar recall measure. At the time, the situation was classified as a Class II recall, indicating a moderate risk to public health.
As defined by the regulatory agency, a Class II recall describes a circumstance where use or exposure to a non-conforming product may generate temporary or reversible health impacts. Alternatively, this classification applies when the chance of serious adverse effects is considered low or unlikely.
In that previous incident, which involved the drugs amlodipine and olmesartan medoxomil, the total volume withdrawn from the market exceeded 15,000 vials.






